
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is poised for continued growth and success, with a strong portfolio of precision diagnostics and radiopharmaceutical products that address unmet needs in the cardiology and oncology markets. The recent approval of Pylarify, a PSMA imaging agent for prostate cancer, and the acquisition of Evergreen Theragnostics and the FDA's approval of its pipeline asset LNTH-2501 are all catalysts for future growth. Additionally, the company's strong financial performance in the first quarter of 2026 and its focus on strategic partnerships and diversification leave it well-positioned for future success.
Bears say
Lantheus Holdings is facing potential issues with third-party manufacturing for their radiopharmaceutical assets, causing delays in potential FDA approval and revenue contribution. Additionally, their Alzheimer's pipeline, while promising in the long term, is not expected to make a significant impact for the next 2-3 years and is dependent on the availability of therapeutic agents. The recent approval of PSMA-PET formulation is a positive development, but the company is facing pricing pressure and margin dilution, which could affect their financial performance in the near term.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares